Impact of Body Composition Changes on Treatment-Related Toxicities and Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Patients Receiving Trastuzumab Deruxtecan.

Cancers (Basel) · 2025 · PMC12468189 · PMID 41008905

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

showed a trendp = 0.063so close (0.05 < p ≤ 0.1)

Kaplan–Meier analysis confirmed that greater reductions in SMA significantly increased the risk of mortality (HR 5.1, 95% CI: 1.05–24.79; p = 0.025) and showed a trend toward higher risk of disease progression (HR 2.58, 95% CI: 0.89–7.49; p = 0.063).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.